Orthofix Medical Inc.: Form 10-K for the period ended Dec 31, 2025
Filed with the SEC on Feb 24, 2026 and accepted by EDGAR at Feb 24, 2026, 12:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $822.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $256.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $566.0m | us-gaap:GrossProfit |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $65.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2025-01-01 to 2025-12-31 | $554.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$81.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$92.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −$2.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$2.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 39,602,345 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | $33.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $34.6m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2025-12-31 | $82.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $416.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $850.6m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $170.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $400.6m | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $157.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-12-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-12-31 | $450.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-26-065189. Last ingested by Listed: Oct 24, 2026, 14:59 ET. Listed shows no prices and gives no investment advice.